- Home
- LYRA
as 06-06-2025 4:00pm EST
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.
| Founded: | 2005 | Country: | United States |
| Employees: | N/A | City: | WATERTOWN |
| Market Cap: | 5.8M | IPO Year: | 2020 |
| Target Price: | $100.00 | AVG Volume (30 days): | 1.9M |
| Analyst Decision: | Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -60.66 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.81 - $37.50 | Next Earning Date: | 05-06-2025 |
| Revenue: | $1,185,000 | Revenue Growth: | -29.46% |
| Revenue Growth (this year): | -23.66% | Revenue Growth (next year): | 1286.17% |
Latest Lyra Therapeutics Inc. News
LYRA Breaking Stock News: Dive into LYRA Ticker-Specific Updates for Smart Investing
Zacks
2 days ago
Lyra Stock Soars 356% in a Week on Strong Rhinosinusitis Study Success
MT Newswires
5 days ago
Top Midday Gainers
GuruFocus.com
5 days ago
Lyra Therapeutics Shares Climb Over 500% After Major CRS Trial Win
MT Newswires
5 days ago
Lyra Says Phase 3 Trial of Nasal Implant for Chronic Rhinosinusitis Meets Endpoints
GlobeNewswire
5 days ago
Lyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in the Treatment of Chronic Rhinosinusitis (CRS)
GlobeNewswire
a month ago
Lyra Therapeutics to Present 52-week Extension Stage Results for ENLIGHTEN 1 Phase 3 Study for LYR-210 for the Treatment of Chronic Rhinosinusitis at COSM 2025
Zacks
a month ago
Lyra Therapeutics, Inc. (LYRA) Reports Q1 Loss, Lags Revenue Estimates
GlobeNewswire
a month ago
Lyra Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
Compare LYRA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LYRA Lyra Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.